Physician profile
Beatrice Bratu
NPI 1275563991
$1,868.04
in general payments reported to CMS, 2019-2025
20 companies · $236 in 2025
The $236 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $521 · 2020: $44.86 · 2021: $22.36 · 2022: $233 · 2023: $320 · 2024: $491 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,046.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $625.65 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Phathom Pharmaceuticals, INC. | $338.16 | 2024 | Voquezna |
| Pentax of America, INC. | $177.65 | 2019-2020 | |
| Janssen Biotech, INC. | $117.62 | 2019-2024 | Simponi, Simponi Aria, Stelara |
| Madrigal Pharmaceuticals | $81.87 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $64.99 | 2019-2022 | |
| Pfizer INC. | $51.61 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.57 | 2019-2023 | Entyvio |
| Enterra Medical, INC. | $46.97 | 2023 | |
| Merck Sharp & Dohme LLC | $43.96 | 2019-2024 | Dificid |
| Genzyme Corporation | $41.10 | 2025 | |
| Intercept Pharmaceuticals, INC. | $36.70 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.33 | 2019-2025 | Xifaxan |
| Ardelyx, INC. | $31.70 | 2023-2024 | Ibsrela |
| Ucb, INC. | $29.21 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $26.43 | 2024 | Sutab, Suflave |
| Celltrion USA INC. | $22.80 | 2025 | Vegzelma |
| Vivus LLC | $22.10 | 2019 | |
| Allergan, INC. | $15.32 | 2019 | |
| Phadia US INC. | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beatrice Bratu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.